Full-Time

Director – TS/MS Dry Products Manufacturing and Commercialization

Posted on 4/18/2026

Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

Compensation Overview

$141k - $246.4k/yr

+ Bonus

Indianapolis, IN, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Data Analysis
Requirements
  • BS and/or MS in Chemistry, Engineering, Pharmacy, or related science with minimum 12 years OR PhD in Chemistry, Engineering, Pharmacy, or related science with minimum 8 years of direct experience in Dry Products Manufacturing and Development/Commercialization.
  • Technical expertise in multiple areas, unit operations, and platforms related to technical support of dry products (oral solid dosage forms) commercial manufacturing as well as experience in development and commercialization of these dosage forms.
Responsibilities
  • Serve as Manufacturing Technical Services/Manufacturing Science representative to work with Product Development, Chemistry, Manufacturing and Controls teams, Manufacturing sites, and applicable functional areas to commercialize new dry oral solid drug products.
  • Leverage prior experience to anticipate commercial manufacturing challenges for new dry products. Work across Development and Manufacturing site(s) to implement appropriate product control strategies based on anticipated needs.
  • Serve as the Global Molecule Steward for select oral solid dosage form drug products.
  • Collaboratively integrate different disciplines such as engineering and analytical science on technical projects, process performance improvements, or control strategy effectiveness.
  • Provide proficient data analysis and conclusions considering technical, Regulatory and Quality compliance, and business needs.
  • Achieve network level results for Lilly’s dry products (oral solid dosage forms) that improve effectiveness of Technical Services/Manufacturing, Lilly Manufacturing, or other parts of the business by driving significant organizational improvement and capability work.
  • Influence global leadership in driving improvements and resolving issues.
  • Provide technical leadership for manufacturing process transfers between Lilly and external manufacturing sites as well as additional technical support/guidance for external manufacturing as needed.
  • Drive appropriate shared learning, alignment and improvement across sites and network level activity according to best practices and technical principles.
  • Ensure that experiments and technical work are well designed and appropriately rigorous.
  • Use first principles and theoretical knowledge to define scientific approaches to support technical expectations.
  • Utilize in depth understanding of materials, process, and product to improve product/process robustness, reduce variability, and provide improvement or advanced application of control strategies across sites and technologies.
  • Collaborate with Project Managers on key product project plans and support timely delivery of milestones with appropriate risk mitigation strategies.
  • Leverage prior experience and knowledge as a recognized Subject Matter Expert to collaborate with Development and manufacturing sites in the optimization of key manufacturing platforms such as continuous manufacturing.
  • Influence Development on new product or platform topics in line with Manufacturing needs.
  • Identify and lead the deployment of other new technology as appropriate.
  • Author technical reports and appropriate sections of regulatory submission and responses as needed.
  • Prepare technical aspects of other Regulatory/Quality based documents and support Regulatory reviews and inspections as needed.
  • Remain current on external pharmaceutical manufacturing trends and innovations.
  • Leverage these to improve strategies and applications for developing and controlling manufacturing processes.
  • Prepare, review, and approve study designs, protocols, technical reports, and other related technical documentation.
  • As a reviewer of technical reports, provide input on the experimental findings and conclusions.
  • Mentor and provide review/coaching to develop other technical resources on scientific approach, technology, as well as business approach and behaviors.
Desired Qualifications
  • Flexibility to interact with multiple partners/functions, regions, and cultures.
  • Demonstrated, strong technical leadership and communication skills. Communicates effectively across disciplines and types of audiences (internal and external) to influence and/or drive common understanding and appropriate actions.
  • Ability to work well independently, as well as in teams. Provides partnership and collaboration across multiple disciplines. Ability to lead teams effectively.
  • Demonstrated, strong analytical and problem-solving abilities.
  • Effective at integrating multiple technology disciplines to drive programs forward.

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • Medicare's GLP-1 Bridge can broaden access to Mounjaro and Zepbound.
  • CVS restored Zepbound coverage and added Foundayo across major formularies.
  • Lilly can redeploy capital from Germany toward U.S. manufacturing expansion.

What critics are saying

  • Medicare's bridge program compresses pricing and shifts volume from premium channels.
  • CVS can re-prefer Wegovy or exclude obesity drugs entirely on sponsor opt-outs.
  • Lilly's tirzepatide concentration makes any safety, supply, or pricing shock severe.

What makes Lilly USA unique

  • Lilly dominates diabetes and obesity with Mounjaro and Zepbound, driving 56% revenue.
  • The company pairs blockbuster commercialization with deep R&D and global manufacturing scale.
  • Recent acquisitions add vaccines and non-viral genetic medicine platforms beyond GLP-1s.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Lilly USA who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-5%

2 year growth

-5%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.

INACTIVE